Despite the dedicated efforts of healthcare providers, the prevalence of obesity in the U.S. increased from 30.5% in 2000 to 41.9% in 2020. Obesity-related conditions (including heart disease, certain cancers, and type 2 diabetes) remain the leading causes of preventable death and place a significant financial burden on the U.S. healthcare system, costing over $173 billion annually.
The introduction of GLP-1 medications, like Ozempic and Wegovy, offers hope for long-term population health improvements. However, the surging demand for these medications is creating a significant strain on employers, with skyrocketing costs becoming an immediate challenge.
At Amino Health, we provide Intelligent Routing for GLP-1s to help employers manage these rising costs while empowering members with effective care solutions.
How It Works:
Why This Matters:
Let’s Build Smarter Care Together
Amino Health is your partner in navigating the complexities of GLP-1 management. With tailored search and support, we ensure members have easy access to affordable, high-quality care.